论文信息 - Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a prospective multicentre cohort study - 字舞流文

Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a prospective multicentre cohort study

A. Mebazaa | Bjoern Peters | J. Staessen | L. Thijs | T. Hansen | G. Maestre | H. Mischak | G. Spasovski | A. Zoufaly | K. Narkiewicz | M. Schwab | J. Metzger | M. Seilmaier | M. Rajzer | M. Banasik | M. Krajewska | U. Schmidt | J. Siwy | M. Hecking | J. Normark | C. Lübbert | B. Stegmayr | Å. Nilsson | T. Feldt | M. Stegemann | S. Schmiedel | R. Wendt | A. Olszanecka | H. Orth | M. Psichogiou | B. Czerwieńska | J. Beige | R. Bellmann-Weiler | B. Neuhaus | B. Jensen | P. Lis | M. Hoffmann | B. Rumpf | E. Dudoignon | M. Dzitkowska-Zabielska | L. Catanese | K. Rothfuss | Justyna Zachciał | Marie-Céline Fournier | H. von der Leyen | L. Fulawka | Yu-ling Yu | D. Basoulis | A. Mikołajewska | P. Marciniak | A. Papkalla | Mercedes Salgueira Lazo | Mercedes Salgueira Lazo | S. Kalbitz | N. Kellner | Stefanie Schroth | Jörg Ermisch | J. Raad | Guenter Weiss | Agnieszka Matera-Witkiewicz | A. Edin | G. Karamanakos | M. Milenkova | A. Canevska-Taneska | Łukasz Fuławka | Harald Rupprecht | Lydia Peruth-Stutzmann | Jonathan M. Schmidt | Daniel Breuer | Fariza Abeud | Badr Louadah | Rocio Molas | Fraile Loreto Rojas | Fabiola Alonso García | I. G. Sánchez | Ioana Cezara Hrom | Andrzej Więczek. | Kei K Asayama | Lucas Lanser | Matthias NE Forsell | Sylke Borstel | Lukas Schmölz | M. Litwin | Ioana Hrom | H. Rupprecht | M. S. Lazo | Mercedes Salgueira Lazo | Alicia Edin | A. Matera-Witkiewicz | A. Zoufaly | Georgios Karamanakos | E. Dudoignon | K. Rothfuss

[1] S. Bhatt,et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study , 2022, The Lancet.

[2] Samuel M. Ostroff,et al. Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis , 2022, The Lancet.

[3] R. Becker,et al. Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium , 2022, Nature Reviews Cardiology.

[4] A. Rodríguez-Morales,et al. Highly mutated SARS-CoV-2 Omicron variant sparks significant concern among global experts – What is known so far? , 2021, Travel Medicine and Infectious Disease.

[5] C. Fernandez-Patron,et al. Biomarkers of ageing and frailty may predict COVID-19 severity , 2021, Ageing Research Reviews.

[6] K. Mccafferty,et al. ARCADIA study protocol: a phase II, randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with diabetes hospitalised with suspected or confirmed COVID-19 , 2021, BMJ Open.

[7] A. Vlahou,et al. Urinary peptidomic profiles to address age-related disabilities: a prospective population study , 2021, The Lancet. Healthy longevity.

[8] A. Mebazaa,et al. CD99 and polymeric immunoglobulin receptor peptides deregulation in critical COVID‐19: A potential link to molecular pathophysiology? , 2021, Proteomics.

[9] Á. Avezum,et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial , 2021, The Lancet.

[10] A. Mebazaa,et al. A urinary peptidomic profile predicts outcome in SARS-CoV-2-infected patients , 2021, EClinicalMedicine.

[11] Christopher M. Horvat,et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 - Preliminary report , 2021, medRxiv.

[12] C. Wanner,et al. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13] Jordan J. Clark,et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score , 2020, BMJ.

[14] K. Bhaskaran,et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients , 2020, Nature.

[15] M. Mann,et al. Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV , 2020, Nature.

[16] L. Dodd,et al. Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[17] Kwok-Hung Chan,et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial , 2020, The Lancet.

[18] J. Staessen,et al. Urinary proteomics combined with home blood pressure telemonitoring for health care reform trial: rational and protocol , 2020, Blood pressure.

[19] A. S. El-Radhi. Urinary , 2019, Paediatric Symptom and Sign Sorter.

[20] P. Schultz,et al. Small molecule-mediated inhibition of myofibroblast transdifferentiation for the treatment of fibrosis , 2017, Proceedings of the National Academy of Sciences.

[21] Richard A. Yamarone,et al. Gross Domestic Product (GDP) , 2017 .

[22] B. Weynand,et al. Polymeric immunoglobulin receptor down-regulation in chronic obstructive pulmonary disease. Persistence in the cultured epithelium and role of transforming growth factor-β. , 2014, American journal of respiratory and critical care medicine.

[23] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[24] M. Johannesson. The relationship between cost-effectiveness analysis and cost-benefit analysis. , 1995, Social science & medicine.